Pill Identifier results for actavis. Search by imprint, shape, color or drug name. Actavis already had a collaboration agreement with Amgen to develop oncology biosimilars, and now has five biosimilars in development in oncology, women’s health and other areas. Last year, the company launched new generic pharmaceuticals globally, including generic versions of Diovan, Lidoderm and Cymbalta. A decade after Teva’s $40.5bn acquisition of Actavis Generics, the deal remains a defining moment for the company. This retrospective explores Teva’s hopes, consequences, leadership shifts, and the firm’s new growth strategy under CEO Richard Francis. “The acquisition of Actavis Generics comes at a time when Teva is stronger than ever—in both our generics and specialty businesses,” said Erez Vigodman, President and CEO, Teva. Learn about Actavis uses, dosage, side effects, food interactions, and more. Get all the details about Actavis from MedicinesFAQ. The best deals are not always the quickest to close, as Teva Pharmaceuticals learned in 2016 after its much-lauded acquisition of Allergan’s generic business, Actavis Generics. In its acquisition of the firm, Teva’s dealmakers coupled two leading generics businesses with complementary strengths. Explore Actavis' diverse portfolio of high-quality pharmaceutical products, including generic medicines, across various therapeutic areas and dosage forms. Discover what drugs does Actavis make and its evolving history, from generic pharmaceuticals to its acquisition by Teva. This guide clarifies its product portfolio and company lineage. Actavis Generics[1] (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc.) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis’ journey from a small U.S. generic drug maker to a global pharma leader is a testament to strategic vision and patient-centricity. While Actavis is no longer part of AbbVie following its sale to Teva in 2023, its legacy continues as the company remains a significant player in generic pharmaceuticals.